Mounzer Agha

6.2k total citations · 1 hit paper
77 papers, 2.1k citations indexed

About

Mounzer Agha is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Mounzer Agha has authored 77 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 48 papers in Hematology and 20 papers in Molecular Biology. Recurrent topics in Mounzer Agha's work include Multiple Myeloma Research and Treatments (30 papers), CAR-T cell therapy research (29 papers) and Acute Myeloid Leukemia Research (22 papers). Mounzer Agha is often cited by papers focused on Multiple Myeloma Research and Treatments (30 papers), CAR-T cell therapy research (29 papers) and Acute Myeloid Leukemia Research (22 papers). Mounzer Agha collaborates with scholars based in United States, Belgium and Israel. Mounzer Agha's co-authors include Stanley R. Riddell, J. M. Goodrich, Philip D. Greenberg, Anastasios Raptis, Michael Boyiadzis, David M. Livingston, Jay Boltax, I Bikel, Ghady Haidar and Alan Wells and has published in prestigious journals such as Science, Cell and Journal of Clinical Oncology.

In The Last Decade

Mounzer Agha

69 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones

1992 1.0k citations Mounzer Agha et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mounzer Agha United States	18	985	792	744	498	456	77	2.1k
Friedhelm R. Schuster Germany	21	595 0.6×	855 1.1×	553 0.7×	398 0.8×	159 0.3×	60	1.7k
Uluhan Sili Türkiye	15	722 0.7×	677 0.9×	574 0.8×	193 0.4×	233 0.5×	41	1.6k
Geraldine M. Gillespie United Kingdom	28	567 0.6×	1.3k 1.6×	3.0k 4.1×	368 0.7×	325 0.7×	56	4.0k
Nicolas Mach Switzerland	25	1.2k 1.2×	223 0.3×	1.6k 2.1×	121 0.2×	553 1.2×	96	3.1k
Georg Stary Austria	27	356 0.4×	464 0.6×	1.4k 1.9×	273 0.5×	394 0.9×	79	2.5k
Mandvi Bharadwaj Australia	28	716 0.7×	1.1k 1.4×	2.0k 2.7×	99 0.2×	466 1.0×	52	3.6k
Michael Koldehoff Germany	23	283 0.3×	559 0.7×	546 0.7×	763 1.5×	242 0.5×	74	1.8k
Julia L. Hurwitz United States	32	636 0.6×	1.4k 1.8×	1.2k 1.7×	138 0.3×	573 1.3×	136	3.4k
Katharina Grabmeier‐Pfistershammer Austria	29	897 0.9×	715 0.9×	1.3k 1.8×	130 0.3×	333 0.7×	86	2.6k
Jan Marsal Sweden	22	561 0.6×	474 0.6×	2.0k 2.8×	74 0.1×	415 0.9×	48	3.0k

Countries citing papers authored by Mounzer Agha

Since Specialization

Citations

This map shows the geographic impact of Mounzer Agha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mounzer Agha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mounzer Agha more than expected).

Fields of papers citing papers by Mounzer Agha

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mounzer Agha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mounzer Agha. The network helps show where Mounzer Agha may publish in the future.

Co-authorship network of co-authors of Mounzer Agha

This figure shows the co-authorship network connecting the top 25 collaborators of Mounzer Agha. A scholar is included among the top collaborators of Mounzer Agha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mounzer Agha. Mounzer Agha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bang, Ji Young, Mounzer Agha, Robert H. Hawes, & Shyam Varadarajulu. (2025). Rate of suitable cases for primary EUS-guided biliary drainage in distal malignant biliary obstruction. Gut. 75(1). 6–9. 1 indexed citations

Arnulf, Bertrand, Tessa Kerre, Mounzer Agha, et al.. (2024). Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D.. Journal of Clinical Oncology. 42(16_suppl). 7505–7505. 2 indexed citations

Sereika, Susan M., Jacqueline Dunbar‐Jacob, Katherine A. Yeager, et al.. (2024). Patterns and predictors of electronically measured oral anticancer medication (OAM) adherence among patients with multiple myeloma (MM).. Journal of Clinical Oncology. 42(16_suppl). 7547–7547.

Cohen, Adam D., Mounzer Agha, Jesús F. San Miguel, et al.. (2024). PCR134 Psychometric Properties of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Analysis of Phase 2 CARTITUDE-2 Study Cohorts A, B, and C. Value in Health. 27(6). S320–S320.

Agha, Mounzer, et al.. (2023). Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need. Blood Reviews. 60. 101095–101095. 11 indexed citations

Lin, Yi, Thomas Martin, Saad Z. Usmani, et al.. (2023). POSTER: MM-309 CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 23. S226–S226. 1 indexed citations

Jagannath, Sundar, Saad Z. Usmani, Jesús G. Berdeja, et al.. (2023). P-275 CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. Clinical Lymphoma Myeloma & Leukemia. 23. S187–S187. 2 indexed citations

Lin, Yi, Saad Z. Usmani, Jesús G. Berdeja, et al.. (2023). MM-309 CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 23. S488–S489.

Agha, Mounzer, et al.. (2021). Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era. Open Forum Infectious Diseases. 8(7). ofab353–ofab353. 107 indexed citations

10.

Posluszny, Donna M., Dana H. Bovbjerg, Karen L. Syrjala, et al.. (2021). Rates and Predictors of Nonadherence to the Post-Allogeneic Hematopoietic Cell Transplantation Medical Regimen in Patients and Caregivers. Transplantation and Cellular Therapy. 28(3). 165.e1–165.e9. 10 indexed citations

11.

Cohen, Yaël C., Adam D. Cohen, Michel Delforge, et al.. (2021). Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2. Blood. 138(Supplement 1). 3866–3866. 20 indexed citations

12.

Dytfeld, Dominik, Binod Dhakal, Mounzer Agha, et al.. (2021). Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5). Blood. 138(Supplement 1). 1835–1835. 26 indexed citations

13.

Redner, Robert L., Jan H. Beumer, Patricia Kropf, et al.. (2018). A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. Leukemia & lymphoma. 59(11). 2595–2601. 10 indexed citations

14.

Posluszny, Donna M., Dana H. Bovbjerg, Karen L. Syrjala, Mounzer Agha, & Mary Amanda Dew. (2018). Correlates of anxiety and depression symptoms among patients and their family caregivers prior to allogeneic hematopoietic cell transplant for hematological malignancies. Supportive Care in Cancer. 27(2). 591–600. 34 indexed citations

15.

Roth, Christine G., David R. Weber, Alison R. Sehgal, et al.. (2016). ICU intervention during induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia. Leukemia Research. 48. 16–19. 1 indexed citations

16.

Agha, Mounzer, Anastasios Raptis, Jing‐Zhou Hou, et al.. (2016). Leukapheresis in patients newly diagnosed with acute myeloid leukemia. Transfusion and Apheresis Science. 55(2). 216–220. 20 indexed citations

17.

Raptis, Anastasios, Jing‐Zhou Hou, Rafic Farah, et al.. (2015). Outcome of acute myeloid leukemia patients with pulmonary nodules of uncertain etiology receiving allogeneic hematopoietic progenitor cell transplant. European Journal Of Haematology. 96(1). 55–59. 1 indexed citations

18.

Fukuta, Yuriko, Robert R. Muder, Mounzer Agha, et al.. (2013). Risk factors for acquisition of multidrug-resistant Acinetobacter baumannii among cancer patients. American Journal of Infection Control. 41(12). 1249–1252. 37 indexed citations

19.

McLaughlin, Brian, Annie Im, Anastasios Raptis, et al.. (2012). Fludarabine and cytarabine in patients with relapsed acute myeloid leukemia refractory to initial salvage therapy. International Journal of Hematology. 96(6). 743–747. 9 indexed citations

20.

Foon, Kenneth A., Robert L. Redner, Anastasios Raptis, et al.. (2011). Fludarabine and cytarabine in patients with acute myeloid leukemia refractory to two different courses of front-line chemotherapy. Leukemia Research. 35(7). 885–888. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact